Evaluación Inmunológica de Terapias Inmunomoduladoras con Inmunoglobulinas y con Células mesenquimales en pacientes inmunosuprimidos por trasplante o por SARS-CoV-2

  1. MONTANCHEZ MATEO, JUDITH
Supervised by:
  1. Javier Alberto Carbone Campoverde Director
  2. José María García Ruiz de Morales Director
  3. Elizabeth Sarmiento Marchese Director

Defence university: Universidad Complutense de Madrid

Fecha de defensa: 30 March 2022

Committee:
  1. Rafael Bañares Cañizares Chair
  2. Manuel Martínez Selles D Oliveira Soares Secretary
  3. Mi Kwon Committee member
  4. María Belén Fernández Puntero Committee member
  5. Eduardo López-Collazo Committee member

Type: Thesis

Teseo: 780140 DIALNET lock_openDocta Complutense editor

Abstract

Infections remain a significant cause of morbidity and increased costs after a solid organ transplant (SOT). Secondary antibody deficiency defined as IgG hypogammaglobulinemia (HGG), has been linked to an increased risk of developing severe infections in this clinical setting. PART 2 To date, November 15, 2021, several intensive research, and clinical trials have been conducted, however, an efficacious treatment for severe and critical COVID-19 patients is lacking. Previous studies have reported that human placental mesenchymal stem cells (pMSCs) have immunomodulatory properties in other inflammatory contexts...